Endo International PLC ENDPQ
Find similar stocks with Morningstar Investor.
Morningstar analysts do not currently cover ENDPQ, but with our powerful screener, you can find stocks in the same sector, industry, or style and filter on our unbiased ratings and valuation metrics.
News
-
Par Pharmaceutical Issues Voluntary Nationwide Recall of Seven Lots of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution
-
Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®
-
Endo Announces Confirmation of Plan of Reorganization
-
Par Pharmaceutical Issues Voluntary Nationwide Recall of One Lot of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution
-
ENDO REPORTS FOURTH-QUARTER 2023 FINANCIAL RESULTS
-
Endo Reaches Resolution with U.S. Department of Justice Regarding Legacy Marketing of Opana® ER
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.08
- Bid/Ask
- $0.06 / $0.07
- Market Cap
- $141,131.77
- Volume/Avg
- 6,756 / 126,229
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Endo International PLC is a specialty pharmaceutical company with a considerable presence in pain management, urology, orthopedics, endocrinology, bariatrics, and others. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The company generates maximum revenue from the Branded Pharmaceuticals segment. Some of its products include XIAFLEX, SUPPRELIN, PERCOCET, TESTOPEL, VASOSTRICT, ADRENALIN, and APLISOL.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 2,931
- Website
- https://www.endo.com
Valuation
|
Metric
|
ENDPQ
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
ENDPQ
Financial Strength
|
Metric
|
ENDPQ
|
|---|---|
Quick Ratio | 2.18 |
Current Ratio | 3.10 |
Interest Coverage | −2,413.65 |
Quick Ratio
ENDPQ
Profitability
|
Metric
|
ENDPQ
|
|---|---|
Return on Assets (Normalized) | −0.21% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
ENDPQ
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Rbwvdtdvp | Vwchddt | $70.9 Bil | |
ZTS
| Zoetis Inc Class A | Nfpplnxpd | Xywm | $68.9 Bil | |
HLN
| Haleon PLC ADR | Pxldshh | Qncnc | $37.5 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Nhpdnzky | Svqxg | $14.7 Bil | |
VTRS
| Viatris Inc | Zrgsvddf | Nzrv | $13.7 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Gvbxyxlb | Bjyp | $11.9 Bil | |
CTLT
| Catalent Inc | Xpcrljpf | Zzpmj | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Nztfypyf | Kghnq | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Ggnmbnmvl | Bxnmt | $3.6 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Vjnvhzlb | Stpnzk | $3.5 Bil |